118 related articles for article (PubMed ID: 31154349)
1. Spontaneous regression of pancreatic cancer with liver metastases.
Saade Lemus P; Anderson K; Smith M; Bullock A
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154349
[TBL] [Abstract][Full Text] [Related]
2. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
3. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
4. Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Cao C; Parikh P; Moezardalan K; Anantharaman A; Azarm A; Lai J
Anticancer Res; 2020 Jul; 40(7):4029-4032. PubMed ID: 32620648
[TBL] [Abstract][Full Text] [Related]
5. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
7. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Ozaki K; Hayashi H; Ikuta Y; Masuda T; Akaboshi S; Ogata K; Matumoto K; Ogawa K; Kamio T; Baba H; Takamori H
Clin J Gastroenterol; 2019 Dec; 12(6):603-608. PubMed ID: 30993652
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
9. Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment.
Shelemey PT; Amaro CP; Ng D; Falck V; Tam VC
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34031062
[TBL] [Abstract][Full Text] [Related]
10. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
11. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Yu K
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
[No Abstract] [Full Text] [Related]
12. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.
Singh H; Perez K; Wolpin BM; Aguirre AJ
J Clin Oncol; 2021 Oct; 39(29):3199-3206. PubMed ID: 34428095
[No Abstract] [Full Text] [Related]
13. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Lima CMSR
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559
[No Abstract] [Full Text] [Related]
14. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
18. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
19. Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report.
Yokoyama T; Makino H; Hirakata A; Ueda J; Takata H; Okusa M; Kawashima M; Tsujino T; Hosone M; Matsushita A; Nakamura Y; Yoshida H
J Nippon Med Sch; 2019 Dec; 86(5):284-290. PubMed ID: 31105119
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]